We are proud to announce that PhenoPath is now a Quest Diagnostics Company.


Comparison of clot-based vs. chromogenic factor Xa procoagulant phospholipid activity assays.

By Bohling SD, Pagano MB, Stitzel MR, Ferrell C, Yeung W, Chandler WL.
Am J Clin Pathol. 2012 Feb;137(2):185-92. doi: 10.1309/AJCPGSJ4NHFQMX9W.

We compared 2 commercial plasma procoagulant phospholipid activity (PPA) assays, chromogenic, using bound annexin V to capture phosphatidylserine-containing microparticles, and clot-based. In both, anionic phospholipids accelerated activation of prothrombin by factor Xa. PPA levels were lower in the chromogenic vs the clot-based assay, with poor correlation between methods: normal samples, mean ± SD, 27 ± 17 vs 590 ± 414 nmol/L (n = 24; r(2) = 0.29) and patient samples, mean ± SD, 45 ± 44 vs 401 ± 330 nmol/L (n = 51; r(2) = 0.26). Recovery of phosphatidylserine added to normal, heparinized, and warfarin plasma samples averaged 109% ± 39% using the chromogenic assay but was higher and more varied (mean ± SD, 176% ± 59%) in the clot-based assay. Lupus anticoagulants caused low recovery in both assays. Removal of microparticles by 0.22-μm filtration reduced PPA by 91% in the clot-based and 65% in the chromogenic assay. The clot-based assay showed higher correlation (r(2) = 0.82 vs 0.23) with flow cytometric platelet microparticle counts. The 2 assays measure different aspects of PPA in plasma, with the chromogenic assay primarily measuring smaller microparticles.

PMID: 22261442 [PubMed - indexed for MEDLINE]
Source: Methodist Pathology Associates, 6565 Fannin, Houston, TX 77030, USA.

View the full article on pubmed.gov>